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University of Minnesota, Minneapolis, MNJohn H. Kersey, MD, a pioneer in bone marrow trans-
plantation and the founding Director Emeritus of the
University of Minnesota Masonic Cancer Center, died
suddenly inMarch at the age of 74. Hewas born inMinnesota
and educated at Dartmouth College and the University of
Minnesota Medical School, where he was a lifetime faculty
member. Dr. Kersey dedicated his life and his professional
career to using laboratory science integrated with bedside
care, to developing new treatments for childhood cancer, to
improving the techniques and success of bone marrow
transplantation, and to always remembering that his
patients were the beneﬁciaries of the research.
John had a remarkable career, which began with labora-
tory research under the mentorship of Drs. Robert Good and
Carlos Martinez followed by clinical training in pediatrics
and oncology with Drs. William Krivit and Mark Nesbit. His
broad studies included sabbaticals on leukemia biology with
Dr. Mel Greaves in 1980 and studies in molecular genetics
with Drs. Stan Korsmeyer and Tom Waldman in 1985. His
initial research training started at the forefront of our
understanding of immunologic tolerance, the application of
hematopoietic cell, and immunologic precursor transfer that
led to successes in the ﬁeld of blood and marrow trans-
plantation that are continued worldwide and beneﬁt many
thousands of patients each year.
Dr. Kersey had an infectious enthusiasm for science and
the translation of preclinical science to the bedside. He
excited his trainees and colleagues and motivated many of
us to open our eyes wider, to work harder, and to bring
creative imagination to the burgeoning ﬁeld of bone
marrow transplantation. He served as an inspiration and
laboratory mentor for many University of Minnesota1083-8791/$ e see front matter  2013 American Society for Blood and Marrow
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generations of hematologists/oncologists, immunologists,
and transplantation physician-scientists who embraced his
mission and now continue his legacy. His published work
spans the ﬁeld, with early reports on tolerance to donor skin
grafts, descriptions of the immunologic and clinical mani-
festations of graft-versus-host disease, to translational
development of fractionate total body radiation and how
augmented radiation and pharmacologic conditioning could
overcome graft resistance, even in recipients of T celle
depleted grafts. In pioneering work, he led analyses of the
immunophenotypic and later the molecular characteriza-
tion of hematologic malignancies to understand their
biology, and to develop immunotherapeutic and ex vivo
purging approaches to autografting. He led the ﬁrst
successful allotransplantations for lymphoma, prospective
comparisons of transplantation versus chemotherapy in the
earliest of donor versus no donor studies, and a landmark
report of autologous purged grafts versus sibling donor
allografts for acute lymphoblastic leukemia. His work was
a prime example of team science and a model for those who
followed in his wake.
Johnwas recognized by his colleagues as a leader, serving
as president of the International Society for Experimental
Hematology and president of the American Society for Blood
and Marrow Transplantation. He served on the National
Cancer Institute (NCI) Board of Scientiﬁc Counselors, the
Executive Committee of the American Society of Hema-
tology, as chair of the Scientiﬁc Advisory Committee of the
Children’s Oncology Group, and as associate editor for Blood,
the Journal of Immunology, and Cancer Research. Recognizing
the need for organized multidisciplinary cancer care at the
University of Minnesota, he was the founding director of the
University of Minnesota Masonic Cancer Center and led its
recognition as an NCI-designed Comprehensive Cancer
Center from 1998.
In these days when competitive funding is even a greater
challenge, John’s record of continuous National Institutes of
Health funding from 1977 to the present, including R01s,
P01s, an Outstanding Investigator Award from the NCI, and
numerous other grants, serves both as a targeted high bar
and a challenge to meet for his colleagues and trainees.
With ferocious scientiﬁc interests and charming but
determined scientiﬁc ambition, he led his friends, colleagues,
and trainees on a quest of investigation that continues to the
present with papers of his still to be published in 2013. But
through it all he remembered the patients whose care was
still imperfect, whose diseases were still misunderstood, and
whose treatments could be improved. This model clinical
investigator taught us all many things, and he will not be
forgotten.Transplantation.
